Rethinking the standard for ductal carcinoma in situ treatment

JAMA Oncology

Volumn 1, Issue 7, 2015, Pages 881-883

  Esserman, Laura ^a   Yau, Christina ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST TUMOR; FEMALE; HUMAN; INTRADUCTAL CARCINOMA; MORTALITY;

BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMANS;

EID: 84964695190     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.2607     Document Type: Editorial

References (15)

1. Lin C, Moore D, DeMichele A, et al. The majority of locally advanced breast cancers are interval cancers. J Clin Oncol. 2009;27:abstract 1503.
2. Ozanne EM, Shieh Y, Barnes J, Bouzan C, Hwang ES, Esserman LJ. Characterizing the impact of 25 years of DCIS treatment. Breast Cancer Res Treat. 2011;129(1):165-173.
3. Esserman LJ, Thompson IM, Reid B, et al. Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol. 2014;15(6):e234-e242.
4. Narod SA, Iqbal J, Giannakeas V, Sopik V, Sun P. Breast cancer mortality after a diagnosis of ductal carcinoma in situ [published online August 20, 2015]. JAMA Oncol. doi:10.1001/jamaoncol.2015.2510.
5. American Cancer Society. Lifetime risk of developing or dying from cancer. Revised October 1, 2014. http://www.cancer.org/cancer/cancerbasics/lifetime-probability-of-developing-or-dying-from-cancer. Accessed June 25, 2015.
6. Hwang ES. CALGB 40903: Phase II single-arm study of neoadjuvant letrozole for ER(+) postmenopausal DCIS. Paper presented at: Alliance for Clinical Trials in Oncology 2014 Group Meeting; May 9, 2014; Chicago, IL. https://www.allianceforclinicaltrialsinoncology.org/main/cmsfile?cmsPath=/Public/Annual Meeting/files/CALGB40903sm.pdf. Accessed June 25, 2015.
7. Ayvaci MU, Alagoz O, Chhatwal J, et al. Predicting invasive breast cancer versus DCIS in different age groups. BMC Cancer. 2014;14(584):584.
8. Wapnir IL, Dignam JJ, Fisher B, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011;103(6):478-488.
9. Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368(11):987-998.
10. Vaidya JS, Wenz F, Bulsara M, et al; TARGIT trialists' group. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet. 2014;383(9917):603-613.
11. Campbell MJMR, Obi-Okoye E, Han B, et al. Characterizing the tumor immune microenvironment (TIME) in high-risk ductal carcinoma in situ. Paper presented at: San Antonio Breast Cancer Symposium, Annual Meeting; December 9-13, 2014; San Antonio, TX.
12. Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013;31(19):2382-2387.
13. Solin LJ, Gray R, Baehner FL, et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2013;105(10):701-710.
14. Margolese RG, Cecchini RS, Julian TB, et al. Primary results, NRG Oncology/NSABP B-35: a clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy. Am Soc Clin Oncol. 2015;33(suppl):abstr LBA500.
15. Cuzick J, Sestak I, Cawthorn S, et al; IBIS-I Investigators. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol. 2015;16(1):67-75.